Bioseparations and Downstream Processing
High-pressure refolding of human vascular endothelial growth factor (VEGF) recombinantly expressed in bacterial inclusion bodies: Refolding optimization, and feasibility assessment
Article first published online: 23 MAY 2011
DOI: 10.1002/btpr.642
Copyright © 2011 American Institute of Chemical Engineers (AIChE)
Additional Information
How to Cite
Cothran, A., John, R. J. St., Schmelzer, C. H. and Pizarro, S. A. (2011), High-pressure refolding of human vascular endothelial growth factor (VEGF) recombinantly expressed in bacterial inclusion bodies: Refolding optimization, and feasibility assessment. Biotechnol Progress, 27: 1273–1281. doi: 10.1002/btpr.642
Publication History
- Issue published online: 10 OCT 2011
- Article first published online: 23 MAY 2011
- Accepted manuscript online: 2 MAY 2011 07:01AM EST
- Manuscript Revised: 22 APR 2011
- Manuscript Received: 25 JAN 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- protein refolding;
- high-pressure technology;
- angiogenesis;
- biomanufacturing;
- homodimer
Abstract
High-pressure has been established as an effective technique for refolding proteins at high concentrations. In this study, high hydrostatic pressure (1–3 kbar) was utilized to refold a homodimeric protein from inclusion bodies and the process was evaluated for large-scale manufacturing feasibility. This research focused on increasing protein concentration while maximizing yield and product quality. Refolding yields of 29–42% were achieved in the absence of urea at 2 kbar and at a protein concentration of 6 g/L. Optimization of the refolding buffer composition via multivariate design of experiments and other process parameters such as refolding pressure, gas sparging, and time under pressure are discussed. Although high-pressure refolding can be considered a viable technology for manufacturing if the gains are clearly identified, in this particular case, the benefits that the high-pressure technology offers do not compensate for the drawbacks of implementing new equipment in an existing facility, and unknown impact of scale-up for this molecule. © 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2011

1520-6033/asset/BTPR_left.gif?v=1&s=a5be2ff5a0fe6ccdaad74a6d128c142e5f71a8da)
1520-6033/asset/BTPR_right.gif?v=1&s=992d113a3e61fc9d3571812359165df86cf830e4)
